US 11,813,264 B2
PAR1 modulation to alter myelination
Isobel A Scarisbrick, Rochester, MN (US); Hye-Sook Yoon, Rochester, MN (US); and Kristen L. Drucker, Oronoco, MN (US)
Assigned to Mayo Foundation for Medical Education and Research, Rochester, MN (US)
Filed by Mayo Foundation for Medical Education and Research, Rochester, MN (US)
Filed on Nov. 16, 2021, as Appl. No. 17/528,103.
Application 17/528,103 is a continuation of application No. 16/776,215, filed on Jan. 29, 2020, abandoned.
Application 16/776,215 is a continuation of application No. 15/815,274, filed on Nov. 16, 2017, abandoned.
Application 15/815,274 is a continuation of application No. 14/793,244, filed on Jul. 7, 2015, abandoned.
Claims priority of provisional application 62/021,566, filed on Jul. 7, 2014.
Prior Publication US 2022/0241282 A1, Aug. 4, 2022
Int. Cl. A61K 31/519 (2006.01); A61K 35/30 (2015.01); A61K 31/7105 (2006.01); A61K 48/00 (2006.01); C12N 15/00 (2006.01); C12N 15/63 (2006.01); C12N 15/85 (2006.01); A61K 35/12 (2015.01)
CPC A61K 31/519 (2013.01) [A61K 31/7105 (2013.01); A61K 35/30 (2013.01); A61K 48/00 (2013.01); A61K 48/0058 (2013.01); A61K 48/0066 (2013.01); C12N 15/00 (2013.01); C12N 15/63 (2013.01); C12N 15/85 (2013.01); A61K 35/12 (2013.01); C12N 2506/03 (2013.01); C12N 2506/08 (2013.01)] 13 Claims
 
1. A method for modulating myelination in a subject, comprising delivering to the subject a plurality of PAR1−/− neural stem cells.